The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease.

Oslo University Hospital200 enrolled

Overview

Define a signature of gut microbiota composition and related metabolites in patients with ST-elevation myocardial infarction, non ST-elevation myocardial infarction and chronic coronary disease (CAD).

A total of 200 patients, allocated to 50 patients with chronic coronary syndrome, 75 patients with non-ST elevation myocardial infarction and 75 patients with ST- elevation myocardial infarction will be included. Clinical information, blood samples and fecal samples will be collected. Fecal and blood samples will be collected once in patients With chronic disease and in patients with acute coronary syndrome; in the acute phase and after 3 months.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Coronary Artery Disease Intestinal Disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Coronary heart disease verified by coronary angiography Exclusion Criteria: * Current infection requiring intravenous antibiotics * Inflammatory bowel disease * Renal failure with creatinine \> 200µmol/L * Hepatic impairment * Pregnancy * Previous bariatric surgery * Colostomy * Active malignant disease

Locations (1)

Department of Cardiology, Oslo University Hospital Ullevål

Oslo, Norway

RECRUITING

Outcomes

Primary Outcomes

Microbiota alpha diversity in myocardial infarction measured as Chao1 Index.

fecal-sample. 16srRNA (Miseq) will be used for sequencing.

Time frame: Within 7 days from inclusion.

Microbiota alpha diversity in myocardial infarction measured as Chao1 Index

fecal-sample. 16srRNA (Miseq) will be used for sequencing.

Time frame: At 3 months follow-up.

Lipopolysaccharide binding protein (LBP) in myocardial infarction